Next Article in Journal
Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?
Next Article in Special Issue
Purine Synthesis Inhibitor L-Alanosine Impairs Mitochondrial Function and Stemness of Brain Tumor Initiating Cells
Previous Article in Journal
Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis
 
 
Article

Article Versions Notes

Biomedicines 2022, 10(2), 317; https://doi.org/10.3390/biomedicines10020317
Action Date Notes Link
article xml file uploaded 29 January 2022 09:25 CET Original file -
article xml uploaded. 29 January 2022 09:25 CET Update -
article pdf uploaded. 29 January 2022 09:25 CET Version of Record https://www.mdpi.com/2227-9059/10/2/317/pdf-vor
article supplementary file uploaded. 29 January 2022 09:25 CET - https://www.mdpi.com/2227-9059/10/2/317#supplementary
article html file updated 29 January 2022 09:26 CET Original file -
article xml file uploaded 8 February 2022 10:15 CET Update -
article xml uploaded. 8 February 2022 10:15 CET Update https://www.mdpi.com/2227-9059/10/2/317/xml
article pdf uploaded. 8 February 2022 10:15 CET Updated version of record https://www.mdpi.com/2227-9059/10/2/317/pdf
article html file updated 8 February 2022 10:30 CET Update -
article supplementary file uploaded. 3 March 2022 07:42 CET - https://www.mdpi.com/2227-9059/10/2/317#supplementary
article html file updated 3 March 2022 07:43 CET Update -
article html file updated 31 July 2022 07:40 CEST Update https://www.mdpi.com/2227-9059/10/2/317/html
Back to TopTop